Alkermes to Present Data on Nemvaleukin Alfa at the Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) will present data on nemvaleukin alfa, an investigational immunotherapy, at the Society of Gynecologic Oncology 2022 Annual Meeting from March 18-21, 2022. The focus will be on outcomes from the ARTISTRY-1 study in platinum-resistant ovarian cancer patients, with a plenary oral presentation scheduled for March 19. Additionally, a poster on the ongoing ARTISTRY-7 study will be presented, comparing nemvaleukin plus pembrolizumab against chemotherapy. These studies aim to evaluate the safety and effectiveness of nemvaleukin in cancer treatment.

DUBLIN, March 1, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present data related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, at the Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women's Cancer, taking place March 18-21, 2022. New data in patients with platinum-resistant ovarian cancer from ARTISTRY-1, a phase 1/2 study evaluating the safety, tolerability and efficacy of intravenously administered (IV) nemvaleukin as a monotherapy and in combination with pembrolizumab (KEYTRUDA^®), will be presented in an oral plenary session. In addition, a trial-in-progress poster from the ongoing ARTISTRY-7 global phase 3 study will be presented. ARTISTRY-7 is evaluating the anti-tumor activity and safety of IV nemvaleukin in combination with pembrolizumab compared to investigator's choice chemotherapy, in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.

Details of the presentations are as follows:

Oral Presentation 
Title: Clinical Outcomes of Ovarian Cancer Patients Treated with the Novel Engineered Cytokine Nemvaleukin Alfa in Combination with the PD-1 Inhibitor Pembrolizumab: Recent Data from ARTISTRY-1 
Presenter: Ira Winer, M.D., Ph.D., Associate Professor, Division of Gynecologic Oncology, Wayne State University and Barbara Ann Karmanos Cancer Institute  
Presentation Date/Time: The oral presentation is scheduled to occur on March 19, 2022 during the Scientific Plenary III session (11:00 a.m. – 12:15 p.m. MST). 

Poster Presentation 
Poster Number: 326 
Title: ARTISTRY-7: A Phase 3, Multicenter Study of Nemvaleukin Alfa, a Novel Engineered Cytokine, in Combination With Pembrolizumab Versus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer 
Presenter: Thomas J. Herzog, M.D., Professor of Obstetrics & Gynecology, Deputy Director, University of Cincinnati Cancer Institute 
Presentation Date: The poster will be available for on-site and virtual viewing beginning March 18, 2022.

About Nemvaleukin Alfa ("nemvaleukin") 
Nemvaleukin is an investigational, novel, engineered fusion protein comprised of modified interleukin-2 (IL-2) and the high affinity IL-2 alpha receptor chain, designed to preferentially expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by selectively binding to the intermediate-affinity IL-2 receptor complex. The selectivity of nemvaleukin is designed to leverage the proven anti-tumor effects of existing IL-2 therapy while mitigating certain limitations.

About the Nemvaleukin Clinical Development Program  
ARTISTRY is an Alkermes-sponsored clinical development program evaluating nemvaleukin as a potential immunotherapy for cancer. The ARTISTRY program is comprised of multiple clinical trials evaluating intravenous and subcutaneous dosing of nemvaleukin, both as a monotherapy and in combination with the anti-PD-1 therapy KEYTRUDA^® (pembrolizumab) in patients with advanced solid tumors. Ongoing trials in the ARTISTRY program include: ARTISTRY-1, ARTISTRY-2, ARTISTRY-3, ARTISTRY-6 and ARTISTRY-7.

About Alkermes plc 
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

KEYTRUDA^® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Alkermes Contacts:   
For Investors: Sandy Coombs, +1 781 609 6377 
For Media: Sourojit Bhowmick, Ph.D., +1 781 609 6397

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-present-data-on-nemvaleukin-alfa-at-the-society-of-gynecologic-oncology-2022-annual-meeting-on-womens-cancer-301492162.html

SOURCE Alkermes plc

FAQ

What data will Alkermes present at the SGO 2022 Annual Meeting regarding ALKS?

Alkermes will present data on nemvaleukin alfa, focusing on the ARTISTRY-1 study results in platinum-resistant ovarian cancer patients.

When is the oral presentation about nemvaleukin alfa scheduled?

The oral presentation is scheduled for March 19, 2022, during the Scientific Plenary III session.

What is the ARTISTRY-7 study presented by Alkermes?

The ARTISTRY-7 study evaluates the anti-tumor activity of nemvaleukin alfa combined with pembrolizumab against standard chemotherapy.

What are the key dates for Alkermes' presentations at the SGO 2022 Annual Meeting?

The meeting will take place from March 18-21, 2022, with specific presentations on March 19.

What is nemvaleukin alfa, and how is it relevant to ovarian cancer treatment?

Nemvaleukin alfa is a novel immunotherapy designed to enhance tumor-killing immune cells while avoiding immunosuppressive cell activation, showing potential in ovarian cancer treatment.